Featured Research

from universities, journals, and other organizations

Scientists identify treatable weakness in lethal form of prostate cancer

Date:
November 29, 2011
Source:
American Association for Cancer Research
Summary:
A recent report suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

Mark Rubin, M.D., professor of pathology and laboratory medicine at Weill Cornell Medical College, said although fewer than 2 percent of men with prostate cancer present with neuroendocrine prostate cancer, the more common prostate adenocarcinoma can also evolve into a neuroendocrine prostate cancer, and the prognosis is grim.

"This is a highly lethal form of prostate cancer," said Rubin. "It is also rare enough that it's hard to get samples. This study is the largest of its kind, and it shows that we may be able to treat this highly aggressive disease."

Rubin and colleagues used next-generation RNA sequencing to profile samples of seven neuroendocrine prostate cancers, 30 prostate adenocarcinomas and five benign samples of prostate tissue.

They found that the genes AURKA and MYCN were overexpressed and amplified in 40 percent of neuroendocrine prostate cancers and in 5 percent of prostate adenocarcinomas.

Moreover, the researchers found that treatment with the investigational aurora kinase (AURKA) inhibitor PHA-739358 inhibited the growth of these neuroendocrine tumors.

Rubin said that PHA-739358 has been studied in prostate cancers before without success, but this may be due to the fact that previously studied prostate cancers were not neuroendocrine cancers.

"Prostate cancer is not a homogenous disease. We need to continue to sort out the aggressive disease from the indolent and treat accordingly," said Rubin.

The study was funded by the Prostate Cancer Foundation, the Ann and William Bresnan Foundation, the Early Detection Research Network and the Department of Defense.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Beltran, D. S. Rickman, K. Park, S. S. Chae, A. Sboner, T. Y. MacDonald, Y. Wang, K. L. Sheikh, S. Terry, S. T. Tagawa, R. Dhir, J. B. Nelson, A. de la Taille, Y. Allory, M. B. Gerstein, S. Perner, K. J. Pienta, A. M. Chinnaiyan, Y. Wang, C. C. Collins, M. E. Gleave, F. Demichelis, D. M. Nanus, M. A. Rubin. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011; 1 (6): 487 DOI: 10.1158/2159-8290.CD-11-0130

Cite This Page:

American Association for Cancer Research. "Scientists identify treatable weakness in lethal form of prostate cancer." ScienceDaily. ScienceDaily, 29 November 2011. <www.sciencedaily.com/releases/2011/11/111117083230.htm>.
American Association for Cancer Research. (2011, November 29). Scientists identify treatable weakness in lethal form of prostate cancer. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2011/11/111117083230.htm
American Association for Cancer Research. "Scientists identify treatable weakness in lethal form of prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2011/11/111117083230.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins